` INCY (Incyte Corp) vs S&P 500 Comparison - Alpha Spread

INCY
vs
S&P 500

Over the past 12 months, INCY has outperformed S&P 500, delivering a return of 14% compared to the S&P 500's 12% growth.

Stocks Performance
INCY vs S&P 500

Loading
INCY
S&P 500
Add Stock

Performance Gap
INCY vs S&P 500

Loading
INCY
S&P 500
Difference

Performance By Year
INCY vs S&P 500

Loading
INCY
S&P 500
Add Stock

Competitors Performance
Incyte Corp vs Peers

S&P 500
INCY
ABBV
AMGN
GILD
VRTX
Add Stock

Incyte Corp
Glance View

Economic Moat
None
Market Cap
12.6B USD
Industry
Biotechnology

Incyte Corporation stands as a significant player in the biopharmaceutical landscape, where its roots are firmly planted in the research and development of novel therapeutics. Founded in 1991, Incyte initially carved its path focusing on genomics before pivoting towards drug development. This transformation catalyzed its growth, anchored by its commitment to discovering innovative ways to tackle unmet medical needs in oncology and inflammation. The company’s forte lies in its robust pipeline of targeted therapies, leveraging small molecules and monoclonal antibodies to alter the course of diseases. Incyte's approach is driven by a deep understanding of the biological pathways that underpin human health, allowing it to develop medicines that offer new hope to patients suffering from debilitating conditions. Incyte's commercial success is largely attributed to its flagship product, Jakafi (ruxolitinib), a groundbreaking oral selective inhibitor of Janus Associated Kinases (JAK1 and JAK2). Approved for the treatment of specific types of myelofibrosis and polycythemia vera, Jakafi represents a crucial revenue stream for the corporation. Beyond Jakafi, Incyte has been fruitful in diversifying its portfolio, fostering collaborative partnerships, and strategically licensing its assets to expand market reach and share risks. This dual strategy of internal innovation and external collaboration not only fuels Incyte’s financial engine but also reinforces its position in a competitive marketplace, as it continuously seeks out new frontiers in medical science to address complex diseases worldwide.

INCY Intrinsic Value
92.09 USD
Undervaluation 29%
Intrinsic Value
Price
Back to Top